TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

M Dreyling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.